Lee Financial CO Neurocrine Biosciences Inc Transaction History

Lee Financial CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $941 - $1,230	-10 Reduced 6.25%	150 $15,000
Q3 2022 Nov 01, 2022	SELL	$92.03 - $107.81 $4,325 - $5,067	-47 Reduced 22.71%	160 $17,000
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $151 - $200	2 Added 0.98%	207 $20,000
Q1 2022 May 11, 2022	BUY	$72.45 - $94.81 $1,521 - $1,991	21 Added 11.41%	205 $19,000
Q4 2021 Feb 08, 2022	BUY	$79.65 - $106.22 $1,911 - $2,549	24 Added 15.0%	184 $16,000
Q2 2021 Aug 04, 2021	BUY	$89.43 - $102.27 $1,788 - $2,045	20 Added 14.29%	160 $16,000
Q1 2020 May 07, 2020	BUY	$75.11 - $113.76 $1,877 - $2,844	25 Added 21.74%	140 $12,000
Q3 2019 Nov 08, 2019	BUY	$83.82 - $101.5 $838 - $1,015	10 Added 9.52%	115 $10,000
Q4 2018 Feb 11, 2019	BUY	$68.32 - $124.36 $7,173 - $13,057	105 New	105 $7,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Lee Financial CO, based on Form 13F filings with the SEC.

Stay updated on Lee Financial CO with notifications on news.